Adapting to a changing landscape: switching to oncology biosimilars
Emma Foreman, Philippe Arnaud, Glenn Myers
Discussing the primary considerations involved in switching from an originator biologic pharmaceutical product to a biosimilar product.
Empowering patients as part of a successful biosimilar switching strategy
Emma Foreman, María-José Tamés
Discussing the importance of patient education concerning treatment regimens involving biosimilars with real-world examples.
Implementing biosimilars: a case study on pharmacovigilance best practice
Glenn Myers, Marta Trojniak
Discussing the added importance of pharmacovigilance during treatment with biosimilars with real-world examples.